Bimekizumab improves joint measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE

Background: Understanding efficacy of biologic treatments in joints in patients with psoriatic arthritis (PsA) and increasing amounts of psoriasis-affected BSA is of interest to clinicians.[1] Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated efficacy and tolerability up to 16 wks in patients with PsA.[2-3]